In part 5 of this Exclusive Interview, Tim Dunn talks with Diabetes in Control Publisher Steve Freed about software that can help medical professionals to interpret the data of the CGM system.
Tim Dunn, Ph.D., is the director of Clinical and Computational Research and an Abbott Volwiler Research Fellow.
Transcript of this video segment:
Freed: Now, it’s interesting. If a patient was to actually check his blood sugars 20 times a day and hand write it and bring it in to the doctor, right now they didn’t even look at the logs anymore.
Dunn: (Laugh) Right.
Freed: Technology has really changed that. Do you have any programs in place for — the family practitioner uses it, now the patient has all this information — well, information is great but if they don’t act upon that information, it’s completely useless. So, the purpose is to use this information, educate the patient. So, I would think it would take more time for the medical professional to educate their patient as to what it means when you eat a corned beef sandwich or a piece of corn, some egg foo young. Do you have any kind of software or programs in place to help the medical professional take that information and show how to use it properly to educate the patient?
Dunn: So, we support educational programs. In fact, we did have a grant session yesterday morning that was very focused on how to interpret the data both on the individual patient level and their thinking about it on a single day but also looking at patterns. And so, we’ve been an early supporter of the ambulatory glucose profile. It was developed by the International Diabetes Center and we’ve incorporated that into our reports and really promoted the consensus from the expert community of the diabetes professionals around how to integrate the data into decision-making, how to summarize it in a meaningful way. And I would say anecdotally, I think we were concerned there would be so much data that the discussion would be long or would be difficult, but what we’re seeing when they look at these summaries, it really highlights quickly the discussion topics for the doctor. And so, it actually makes the interaction higher quality, of discussing details that before they just didn’t have any visibility about it. So, I think everybody could use more time with their doctor but I think that they’re using it in a more efficient way when they’d have the data in front of them and that they can share the decision making about what is the problem we want to focus on and what can we do about it.
Freed: Technology changes rapidly at least in the field of diabetes and sensors. And I remember I had the Biographer or the GlucoWatch, I still have scars from. (Laughs) So, technology — I give them credit. They were the first.
Freed: Okay. And from that research and —
Dunn: I actually worked at that company too. (Laughs)
Freed: So, what’s in the pipeline for Abbott because your competition has it on an iPhone. It’s a little bit easier to use. And I just assume that yours will be on an iPhone too.
Dunn: Yeah. So, we do — outside the US, we do already have both Android and IOS, iPhone version of an app that can be used instead of the Reader, and so that’s a big step forward. And we also have a way for the second app to share date between caregivers and the patient. And so, that’s an area we want to keep focusing on. And we agree, we want it to be convenient and accessible to the patient obviously by not needing a Reader, that’s another item they don’t need to purchase. And so, that’s definitely on the horizon for things we want to focus on.